22 Jul Orca Bio
Dan Kirby, Chief Commercial Officer
Oct. 7 | 5:00pm | FLW Ballroom F
Menlo Park, CA
(Private)
Orca Bio is a late-stage cell therapy company engineering high-precision cell therapies for the treatment of blood cancer and autoimmune diseases. Our pipeline of T-cell immunotherapies are designed to replace patients’ diseased blood and immune system with healthy ones. Today, we’re focused on redefining the traditional stem cell transplant by developing cell therapies that provide significantly better outcomes with dramatically fewer toxicities, like GvHD, than the standard of care. Our lead investigational product, called Orca-T, is currently being evaluated in Precision-T, a pivotal Phase 3 clinical trial for the treatment of blood cancers and other hematological malignancies. We announced in June we had completed enrollment and anticipate sharing topline results in the first half of 2025. In parallel, we’re advancing our next-generation programs to expand our pipeline to bring cell therapy to all patients who could benefit, including potential future application in autoimmune disease and genetic disorders. Our mission is to make curative cell therapies both safer and more effective, and in doing so, push past the field’s current boundaries and redefine its future.
